My patient is Signatera™-positive. Now what?
Translating MRD detection into action
Date: Friday, June 26, 2026
Time: 12:00 PM PT | 3:00 PM ET
Webinar duration: 30 minutes
Registrants will receive a recording of the webinar approximately one week after the event.
As molecular residual disease (MRD) testing becomes increasingly integrated into oncology practice, clinicians are tackling important questions around interpretation, treatment planning, and patient communication following ctDNA positivity.
This webinar will provide a practical framework for managing patients with a positive Signatera™ result across multiple cancer types and settings including:
- How ctDNA positivity can inform surveillance strategies, multidisciplinary discussions, clinical trial enrollment and therapeutic considerations in a real-world practice
- The correlation between MRD positivity, recurrence risk and importance of tracking ctDNA trends over time through longitudinal monitoring
- Viewers will come away with practical approaches for interpreting positive MRD results and navigating the vital role of ctDNA centered around patient quality of life.